Globus Medical falls on Goldman downgrade

"We see the recent Aetna policy change to deny coverage for cervical interbody devices as shaving approximately 0.8%-0.9% off of our prior 2014 revenue estimates alone," Goldman's David Roman says, adding that the figure "could become more meaningful if additional commercial payers follow suit."

Globus Medical (GMED) is downgraded to Neutral from Buy and Goldman's FY14, FY15, and FY16 revenue projections are cut by 0.9%, 1%, and 1.4% respectively.

Price target cut to $18 from $19.

GMED -3.6% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs